Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma

Conclusions AdV-tk can be safely combined with pancreatic cancer SOC without added toxicity. Response and survival compare favorably to expected outcomes and immune activity increased. These results support further evaluation of GMCI with more modern chemoradiation and surgery as well as PD-1/PD-L1 inhibitors in pancreatic cancer.

http://link.springer.com/10.1007/s00262-015-1679-3

Source: Cancer Immunology, Immunotherapy - March 21, 2015 Category: Cancer & Oncology Source Type: research